Consult patients and caregivers on the following:.

Household members (including children) or other close contacts at risk for accidental ingestion or overdose.

Based on patient’s risk factors for overdose (eg, concomitant use of CNS depressants, a history of opioid use disorder, prior opioid overdose) presence of risk factors should not prevent proper pain management.

Assess need for naloxone upon initiating and renewing treatment.

Renal impairment: Elimination half-life prolonged with end-stage renal impairment dose reduction may be required Dosing ConsiderationsĪdjust dose according to severity of pain and patient responseĮxtended-release (Xartemis XR) is a bilayer formulation of oxycodone and acetaminophen (contains immediate- and extended-release layers) which is not interchangeable with other oxycodone/acetaminophen products because of differing pharmacokinetic profiles Access to naloxone for opioid overdose Hepatic impairment: Reduce dose in cases of severe impairment

Intermittent or breakthrough pain: Administer as needed Dosage Modifications Not to exceed total 4 g/day of acetaminophen (total daily dose from any source)Ĭhronic pain: Administer as scheduled dosing around the clock Not to exceed total 4 g/day of acetaminophen (total daily dose from any source) Moderate-to-Severe Painĥ mg/325 mg, 7.5 mg/500 mg, 10 mg/650 mg: 1 tablet PO q6hr The second dose of 2 tablets may be administered as early as 8 hr after the initial dose if analgesia required at that time subsequent doses are to be administered 2 tablets q12hr Indicated for management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequateĮxtended-release tablet (Xartemis XR): 2 tab PO q12hr without regard to food Oxycodone/acetaminophen tablet: Schedule II

Acetaminophen davis pdf